PharmAust Receives $546K R&D Rebate from ATO
160201_PharmAust Receives $546K R&D Rebate from ATO
Appendix 4C – Quarterly Report & Company Update
160129_Appendix 4C – Quarterly Report & Company Update
USA Roadshow Presentation – January 2016
160118_USA Roadshow Presentation – January 2016
Juniper Pharma Services to reformulate MPL for Phase II
160111_Juniper Pharma Services to reformulate MPL for Phase II
PharmAust Featured on RedChip Money Report on Bloomberg
160104_PharmAust Featured on RedChip Money Report on Bloomberg
Epichem Awarded Two Year Contract Extension from DNDi
151221_Epichem Awarded Two Year Contract Extension from DNDi
Appendix 3B & 708 Notice
151204_Appendix 3B & 708 Notice
Change of Director’s Interest Notice
161213_Change of Director’s Interest Notice
GenScript Further Pre-Clinical Validation for Phase II Trial
151126_GenScript Further Pre-Clinical Validation for Phase II Trial
RedChip appointed to begin Global Investor Relations Program
151124_RedChip appointed to begin Global Investor Relations Program